Evidence map›Paper›PMID 26336889›Full record

ArticleBMC musculoskeletal disorders2015

Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting.

Kashif Jafri, Lynne Taylor, Melissa Nezamzadeh, Joshua F Baker, Nehal N Mehta, Christie Bartels, Catherine T Williams, Alexis Ogdie

Open access · goldAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC musculoskeletal disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kashif JafriDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Kashif.jafri@uphs.upenn.edu.
Lynne TaylorBiostatistics Analytic Core, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. @mail.med.upenn.edu.
Melissa NezamzadehCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. melnezam@gmail.com.
Joshua F BakerDivision of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, White Building, Room 5024, 3400 Spruce St., Philadelphia, PA, 19104, USA. Joshua.baker@uphs.upenn.edu.
Nehal N MehtaSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. Nehal.mehta@nih.gov.
Christie BartelsDivision of Rheumatology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Cb4@medicine.wisc.edu.
Catherine T WilliamsBiostatistics Analytic Core, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. smithct@mail.med.upenn.edu.
Alexis OgdieDivision of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, White Building, Room 5024, 3400 Spruce St., Philadelphia, PA, 19104, USA. alexis.ogdie@uphs.upenn.edu.
University of Pennsylvania · USCancer Research And Biostatistics · USNational Heart Lung and Blood Institute · USUniversity of Wisconsin–Madison · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
Identification of Early Psoriatic ArthritisK23AR063764 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI OGDIE, ALEXIS R. · 2013 to 2017
$751k
Body composition, bone structure, and joint damage in rheumatoid arthritisIK2CX000955 · VA · PHILADELPHIA VA MEDICAL CENTER · PI BAKER, JOSHUA F. · 2013 to 2017
–
CSRD VA IK2 CX000955NCATS NIH HHS UL1 TR000427NIAMS NIH HHS K23 AR063764NIAMS NIH HHS K23AR063764
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) has been associated with an increased risk of cardiovascular morbidity and mortality but this has not translated to optimal management of traditional cardiovascular risk factors such as hyperlipidemia. The objectives of this study were to 1) determine the prevalence of screening for hyperlipidemia in patients with RA followed by primary care practitioners (PCP); 2) examine initiation of lipid-lowering therapy in patients with an indication, and 3) assess whether proposed modifications to cardiovascular risk calculations change the percentage of RA patients with an indication for therapy.

methodsWe performed a retrospective cohort study using an academic medical center-based medical record database in the United States. Patients with RA defined by the presence of at least one ICD-9 code between 2005-2010 and followed by a PCP within the health care system were included. The positive predictive value of ICD-9 codes for accurately identifying patients with RA was 96.7%. Descriptive statistics were used to report the prevalence of screening and use of lipid-lowering therapy among those with an indication. Factors associated with not receiving lipid screening were examined using logistic regression models. Indication for and receipt of therapy were then assessed before and after the application of the European Union League Against Rheumatism (EULAR) recommended multiplier to the Framingham risk score.

resultsAmong 1,056 patients with RA followed by PCPs and eligible for lipid screening, lipid screening was ordered for 539 (51%) within the 3-year follow-up period. Patients with diabetes, hypertension, chronic kidney disease, obesity or age >50 were more likely to be screened. Of those with lipid results (N = 290), 25 (9%) patients had an indication for lipid-lowering therapy based on Adult Treatment Panel III guidelines. Ten (40%) patients with an indication for lipid-lowering therapy received therapy did not receive therapy. Applying the EULAR multiplier only changed the indication for lipid-lowering therapy in two patients.

conclusionsScreening and management of traditional cardiovascular risk factors, including hyperlipidemia, need to be optimized.

Indexed as

Disease ManagementAdultAgedArthritis, RheumatoidCohort StudiesFemaleHumansHyperlipidemiasMaleMiddle AgedPrimary Health CareRetrospective Studies

Identifiers

PMID26336889
PMCPMC4559905
OpenAlexW2134684382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.